https://scholars.lib.ntu.edu.tw/handle/123456789/543232
標題: | Exploring the benefit of 2-methylbutyric acid in patients undergoing hemodialysis using a cardiovascular proteomics approach | 作者: | Wu, P.-H. Chiu, Y.-W. Zou, H.-B. CHENG-CHIH HSU Lee, S.-C. Lin, Y.-T. Tsai, Y.-C. Kuo, M.-C. Hwang, S.-J. |
關鍵字: | 2-methylbutyric acid; Bone morphogenetic protein 6; End-stage renal disease; Hemodialysis; Short-chain fatty acids; Target proteomics | 公開日期: | 2019 | 卷: | 11 | 期: | 12 | 起(迄)頁: | - | 來源出版物: | Nutrients | 摘要: | Short-chain fatty acids (SCFAs) can reduce pro-inflammatory parameters and oxidative stress, providing potential cardiovascular (CV) benefits. Although some evidence links SCFAs with host metabolic health via several biological mechanisms, the role of SCFA on CV disease in patients with kidney disease remains unclear. Herein, we investigate the association between a SCFA, 2-methylbutyric acid, and target CV proteomics to explore the potential pathophysiology of SCFA-related CV benefit in patients with kidney disease. Circulating 2-methylbutyric acid was quantified by high-performance liquid chromatography and 181 CV proteins by a proximity extension assay in 163 patients undergoing hemodialysis (HD). The associations between 2-methylbutyric acid and CV proteins were evaluated using linear regression analysis with age and gender, and multiple testing adjustment. The selected CV protein in the discovery phase was further confirmed in multivariable-adjusted models and evaluated by continuous scale association. The mean value of circulating 2-methylbutyric acid was 0.22 ± 0.02 ?M, which was negatively associated with bone morphogenetic protein 6 (BMP-6) according to the false discovery rate (FDR) multiple testing adjustment method. The 2-methylbutyric acid level remained negatively associated with BMP-6 (β coefficient ?1.00, 95% confidence interval ?1.45 to ?0.55, p < 0.001) after controlling for other CV risk factors in multivariable models. The cubic spline curve demonstrated a linear relationship. In conclusion, circulating 2-methylbutyric acid level was negatively associated with BMP-6, suggesting that this pathway maybe involved in vascular health in patients undergoing HD. However, further in vitro work is still needed to validate the translation of the mechanistic pathways. ? 2019 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://www.scopus.com/inward/record.url?eid=2-s2.0-85076700347&partnerID=40&md5=e1a2aa2dc160b71ba50e11cafdab9a30 https://scholars.lib.ntu.edu.tw/handle/123456789/543232 |
DOI: | 10.3390/nu11123033 | SDG/關鍵字: | 2 methylbutyric acid; bone morphogenetic protein 6; C reactive protein; calcium; phosphate; short chain fatty acid; 2-methylbutanoic acid; BMP6 protein, human; bone morphogenetic protein 6; butyric acid derivative; adult; arteriovenous fistula; Article; blood sampling; cardiovascular risk; comorbidity; controlled study; diastolic blood pressure; disease course; end stage renal disease; female; hemodialysis; high performance liquid chromatography; human; hypertension; limit of detection; major clinical study; male; middle aged; polymerase chain reaction; prescription; protein expression; proteomics; quality control; systolic blood pressure; aged; blood; cardiovascular disease; cardiovascular system; chemistry; chronic kidney failure; complication; pathophysiology; proteomics; Adult; Aged; Bone Morphogenetic Protein 6; Butyrates; Cardiovascular Diseases; Cardiovascular System; Female; Humans; Male; Middle Aged; Proteomics; Renal Dialysis; Renal Insufficiency, Chronic |
顯示於: | 化學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。